Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Impact of Difficult to Treat Sites on Biological Treatment Response in Patients With Moderate-to-Severe Plaque Psoriasis

NCT04428411 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT04428411
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04428411 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Impact of Difficult to Treat Sites on Biological Treatment Response in Patients With Moderate-to-Severe Plaque Psoriasis
Lead sponsor
Pfizer
Phase
Observational
Overall status
Completed
Start date
July 5, 2020
Completion date
August 30, 2020
Enrollment
486 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

plaque psoriasis